Roland Walder

Part of Syneos Health, Inc., NDDO Oncology BV provides product development support to pharmaceutical and biotechnology companies. The company is based in Amsterdam, Netherlands. The Dutch company was founded by Herbert Michael Pinedo. NDDO Oncology was acquired by Syneos Health NC LLC, part of Syneos Health, Inc. from December 31, 2010 on December 01, 2005.

Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Aglaia Management BV is an independent venture capital investment firm headquartered in Bilthoven, the Netherlands. In 2003, Aglaia was co-founded by Mark Krul and Karl Rothweiler.

Visiopharm A/S provides quantitative digital pathology solutions for biopharmaceutical companies, contract research organizations, academic medical centers, research institutes and hospitals. Its offers solutions such as BIOTOPIX, ONCOTOPIX, and STEREOTOPIX. The company was founded by Michael Grunkin and Johan Doré Hansen in 2001 and is headquartered in Horsholm, Denmark.

ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands.

ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands.

SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark.

Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark.

Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland.

SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands.

Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany.

Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands.

apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany.

Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands.

Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom.

ApoGen Biotechnologies, Inc. operates as a biotechnology firm, which focuses on the development of therapeutics targeting drivers of cancer genomic mutation. The company was founded by John T. Santini, Jr., Reuben S. Harris, and Daniel A. Harki in 2014 and is headquartered in Seattle, WA.

iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland.

Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark.

Part of Novo Nordisk A/S, Bioinnovation Institute is a Danish company that offers entrepreneurs and researchers in life science. The company is based in Copenhagen, Denmark. The CEO of the company is Jens Nielsen.

TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany.

Bii Holdings A/S is a non-profit organization that operates an incubator for startup businesses in science and technology. The Danish company was founded by Doron Cohen.